Hamill John P.'s Form 4 filing
Aprea Therapeutics, Inc. (APRE) · filed Oct 15, 2024
- Accession no.
- 0001104659-24-108373
- Filed
- Oct 15, 2024
- Trade date
- Oct 10, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $1.17K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamill John P.CIK 0001716213 | Officer (SrVP/CFO/Prin Fin & Acct Ofcr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 10, 2024 | Common Stock | PPurchaseAcquired | +450 | $2.61F1 | +$1,174.5 | 19,318 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.55 to $2.618, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.